display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - adjuvantbreast cancer - HR positive
breast cancer - adjuvantla/mBC - HR positivela/mBC - HR-positive - 1st line (L1)la/mBC - HR-positive - 2nd line (L2)
cyclin inhibitor
abemaciclib based treatment
abemaciclib plus aromatase inhibitor MONARCH 3
abemaciclib plus endocrine therapy MonarchE MonarchE
abemaciclib plus fulvestrant MONARCH 2
dalpiciclib plus fulvestrant DAWNA-1
palbociclib based treatment
palbociclib PALLAS
palbociclib plus endocrine therapy PENELOPE-B KCSG-BR15-10 PENELOPE-B
palbociclib plus fulvestrant FLIPPER PALOMA-3
palbociclib plus letrozole PALOMA-1 PALOMA-2
ribociclib based treatment
ribociclib plus endocrine therapy MONALEESA-7
ribociclib plus fulvestrant MONALEESA-3
ribociclib plus letrozole MONALEESA-2

Study type: